Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 3/20 | 0.45 |
| ▸ | SLC9A1 | P19634 | 2/20 | 0.38 |
| ▸ | HTR2C | P28335 | 4/20 | 0.36 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.34 |
| ▸ | PNMT | P11086 | 1/20 | 0.34 |
| ▸ | PLG | P00747 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5756057 | 1.00 | HTR1A (0.45) | HTR1ASLC9A1HTR2CP2RY14PNMT | |
| SCHEMBL5758860 | 1.00 | HTR1A (0.45) | HTR1ASLC9A1HTR2CP2RY14PNMT | |
| SCHEMBL5758589 | 0.86 | HTR1A (0.41) | HTR1APLG | |
| SCHEMBL5760366 | 0.86 | HTR1A (0.41) | HTR1APLG | |
| SCHEMBL5758594 | 0.86 | HTR1A (0.41) | HTR1APLG | |
| SCHEMBL5758273 | 0.82 | HTR1A (0.43) | HTR1APLG | |
| SCHEMBL5756274 | 0.82 | HTR1A (0.43) | HTR1APLG | |
| SCHEMBL5756271 | 0.82 | HTR1A (0.43) | HTR1APLG | |
| SCHEMBL5856322 | 0.81 | CA2 (0.38) | HTR1APLG | |
| SCHEMBL5759705 | 0.81 | CA2 (0.38) | HTR1APLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7144898-B2 | Indole derivatives for the treatment of depression and anxiety | ELI LILLY AND COMPANY (US) | 2006-12-05 | — | — | US | disclosed |
| EP-1242411-B1 | INDOLE DERIVATIVES FOR THE TREATMENT OF DEPRESSION AND ANXIETY | LILLY CO ELI (US) | 2006-03-08 | — | — | EP | disclosed |
| US-20040006229-A1 | Indole derivatives for the treatment of depression and anxiety | ELI LILLY AND COMPANY | 2004-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006229-A1 | Indole derivatives for the treatment of depression and anxiety | IDO1, TPH1, IDO2 | HTR1A 4/4885SLC9A1 2152/4885HTR2C 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.